Adjuvant interferon-α-2b cost effective in high-risk melanoma

1997 ◽  
Vol 133 (1) ◽  
pp. 7-7
Keyword(s):  
High Risk ◽  
Cost Effective ◽  
Interferon Α ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Adjuvant Interferon

scholarly journals Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

2017 ◽  
Vol 82 ◽  
pp. 171-183 ◽  
Author(s):  
Natalie J. Ives ◽  
Stefan Suciu ◽  
Alexander M.M. Eggermont ◽  
John Kirkwood ◽  
Paul Lorigan ◽  
...  
Keyword(s):  
High Risk ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data ◽  
Interferon Α ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Adjuvant Interferon

Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

2003 ◽  
Vol 29 (4) ◽  
pp. 241-252 ◽  
Author(s):  
Keith Wheatley ◽  
Natalie Ives ◽  
Barry Hancock ◽  
Martin Gore ◽  
Alexander Eggermont ◽  
...  
Keyword(s):  
High Risk ◽  
Meta Analysis ◽  
Interferon Α ◽  
Randomised Trials ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Adjuvant Interferon

The prevalence of autoantibodies in patients with high risk melanoma receiving adjuvant interferon

2004 ◽  
Vol 14 (4) ◽  
pp. A17 ◽  
Author(s):  
H. Gogas ◽  
J. Ioannovich ◽  
K. Frangia ◽  
D. Tsoutsos ◽  
P. Panagiotou ◽  
...  
Keyword(s):  
High Risk ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Adjuvant Interferon

scholarly journals Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

2010 ◽  
Vol 8 (1) ◽  
Author(s):  
Helen Gogas ◽  
Urania Dafni ◽  
Henry Koon ◽  
Maria Spyropoulou-Vlachou ◽  
Yannis Metaxas ◽  
...  
Keyword(s):  
High Risk ◽  
Interferon Therapy ◽  
Multicenter Trial ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Adjuvant Interferon

Correlation of molecular HLA typing and outcome in high-risk melanoma patients receiving adjuvant interferon

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8029-8029
Author(s):  
H. Gogas ◽  
M. Spyropoulou-Vlachou ◽  
U. Dafni ◽  
D. Tsoutsos ◽  
C. Markopoulos ◽  
...  
Keyword(s):  
High Risk ◽  
Hla Class I ◽  
Antigen Expression ◽  
Class I ◽  
Healthy Controls ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Adjuvant Interferon ◽  
Group 1

8029 Background: Serological typing for both HLA class I and class II antigen expression, has previously shown association of specific HLA antigen expression with clinical response and survival in patients with metastatic melanoma treated with IL-2 (e.g. HLA-DQ1). Purpose: To evaluate the impact of HLA class I (low-resolution) and class II (high-resolution) expression, on the outcome of high-risk melanoma patients receiving adjuvant high-dose interferon. Methods: 181 stage IIB, IIC and III melanoma patients (88 female and 93 male), median age 52.1 years and 246 healthy controls were included in this study. DNA was used for the determination of HLA-A, HLA-B, HLA-Cw, HLA-DRB1 and HLA-DQB1 genotypes. Results: With a median follow-up of 37 months, 59 (group 1) patients have remained with no evidence of recurrence and 122 have recurred (group 2). Statistical significant differences between the two groups, were found in the following genotypes: HLA-A*02 (42% vs. 57.3%, p=0.08), HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 34.4%, p=0.01), HLA-B*57 (11.8% vs. 2.4%, p=0.02). Statistical significant differences between group 1 and healthy controls, were found in the following genotypes: HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 28.5%, p=0.05), HLA-B*57 (11.8% vs. 4.5%, p=0.05), HLA-Cw*03 (23.7% vs. 11%, p=0.01), HLA-Cw*06 (27.1% vs. 16.1%, p=0.06), HLA-DRB1*0701 (27.1% vs. 13.4%, p=0.01), HLA-DRB1*1601 (35.6% vs. 22.3%, p=0.01), HLA-DQB1*0202 (23.8% vs. 10.1%, p=0.09). Conclusions: Statistical significant differences were seen in HLA-A and HLA-B alleles between the patients with high-risk melanoma free of recurrence and those who recurred after treatment with adjuvant interferon. Additionally, differences were seen between healthy controls and melanoma patients free of recurrence. No significant financial relationships to disclose.

Meyerson’s phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α

2012 ◽  
Vol 22 (3) ◽  
pp. 284-285 ◽  
Author(s):  
Elisa Zonta ◽  
Vanna Chiarion ◽  
Haik Zarian ◽  
Andrea Peserico ◽  
Mauro Alaibac
Keyword(s):  
High Risk ◽  
Interferon Α ◽  
High Risk Melanoma ◽  
Risk Melanoma

The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma

2017 ◽  
Vol 16 (8) ◽  
pp. 933-940 ◽  
Author(s):  
Van Anh Trinh ◽  
Chrystia Zobniw ◽  
Wen-Jen Hwu
Keyword(s):  
High Risk ◽  
Interferon Alfa ◽  
Efficacy And Safety ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Adjuvant Interferon

scholarly journals Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

2010 ◽  
Vol 67 (3) ◽  
pp. 657-666 ◽  
Author(s):  
A. I. Daud ◽  
C. Xu ◽  
W.-J. Hwu ◽  
P. Urbas ◽  
S. Andrews ◽  
...  
Keyword(s):  
High Risk ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Pharmacodynamic Analysis

Interferon-α in high-risk melanoma patients

2004 ◽  
Vol 4 (6) ◽  
pp. 667-676 ◽  
Author(s):  
Janice N Cormier ◽  
Yan Xing ◽  
Merrick I Ross ◽  
Scott B Cantor
Keyword(s):  
High Risk ◽  
Interferon Α ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document